Context

Celyad is a Phase I European biotech company focused on the development of innovative CAR-T cell therapy.

Its lead candidate CYAD-01, is leveraging the differentiated receptor NKG2D, which is being developed for the treatment of hematological malignancies and solid tumors.

The company has had promising Phase I data, with positive responses in several leukemia patients and the stabilization of colorectal and ovarian cancer diseases in some patients.

The company is currently using a combination trio of disruptive, first-in-class, non-gene-edited allogenic CAR-Ts which are due to enter clinics in 2020-21.

Celyad has a strong expertise in cell therapy manufacturing; all of its facility and global logistics capabilities are centralized in-house.

Celyad enjoys a strong intellectual property position owing to their NKG2D CAR-T technology. In 2017, Celyad granted Novartis a non-exclusive license for allogeneic TCR deficient CAR-T cells patents.

The global equity offering was aimed to further finance its R&D effort and general corporate purposes.

About Celyad

Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based product candidates and utilizes its expertise in cell engineering to target cancer. Celyad’s CAR-T cell platform has the potential to treat a broad range of solid and hematologic tumors. The company’s lead clinical candidate, CYAD-01, an autologous NKG2D-based CAR-T therapy, is currently being evaluated in several Phase 1 clinical trials to assess safety and clinical activity for the treatment of hematological malignancies, such as acute myeloid leukemia, and solid cancers, such as metastatic colorectal cancer. Celyad is also developing CYAD-101, an investigational, non-gene edited, allogeneic (donor derived) NKG2D-based CAR-T therapy, which is currently being evaluated in a Phase 1 trial for the treatment of patients with metastatic colorectal cancer. Celyad was founded in 2007 and is based in Mont Saint-Guibert, Belgium, and New York, NY. Celyad’s ordinary shares are listed on the Euronext Brussels and Euronext Paris exchanges, and its American Depository Shares are listed on the Nasdaq Global Market, all under the ticker symbol CYAD.

Discover Celyad

Pierre Kiecolt-Wahl

Investment Banking

Cosme Rosellini

Investment Banking

Vincent Meunier

Investment Banking

Pierre Sertour

Equity Capital Markets

Pierre Sertour photo

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

Privacy Preference Center